GT Biopharma (NASDAQ:GTBP – Get Free Report) will likely be posting its results before the market opens on Wednesday, April 1st. Analysts expect GT Biopharma to post earnings of ($0.22) per share for the quarter.
GT Biopharma Stock Up 1.4%
NASDAQ:GTBP opened at $0.48 on Wednesday. The firm has a market capitalization of $14.99 million, a price-to-earnings ratio of -0.07 and a beta of 1.28. GT Biopharma has a twelve month low of $0.39 and a twelve month high of $3.85. The stock’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.66.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e)” rating on shares of GT Biopharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
About GT Biopharma
GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.
The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).
Read More
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
